Pudgy Penguins NFTs surpass Bitcoin as floor price breaks $100K Ivar AI

Ambcrypto.com

Crypto market cap surpasses France, UK GDPs – India, Japan next

The Times of India

SoundHound: This AI stock rose 578% in 2024, how will it perform in 2025; why investors are gung-ho about this company? Here are its unique selling points

Futurism

SpaceX Now More Valuable Than McDonald's and Coca-Cola

Decrypt

Google’s New Willow Chip Accelerates Time to Market for Quantum Computing, Experts Say

Terra.com.br

Irã pode estar a um passo da bomba nuclear, alerta ONU

Electrek

Glencore + Cyclic Materials go large on copper recycling for EVs, clean energy

Biztoc.com

Israel captures Syrian territory after Assad regime collapse

newsBTC

Ethereum Price Breakout: Charting The Uncertain Part Of ETH To $18,000

newsBTC

Bitcoin Nears $100,000: Market Expert Predicts $200K Surge Amid Retail FOMO And Volatility

The Daily Hodl

Crypto Investment Products Break Previous Record With $3,850,000,000 in Weekly Inflows: CoinShares

GlobeNewswire

TECVAYLI®▼ (teclistamab) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma

ABC News

Five years since its inception, a US development agency competes with China on global projects

International Business Times

Taiwan Says China Carrying Out Huge Maritime Drills

The Daily Hodl

Trader Turns $3,000 Investment Into $73,000,000 With Frog-Themed Memecoin PEPE: Lookonchain

Xataka.com.co

Estados Unidos y Colombia lanzan alianza de seguridad para combatir el crimen organizado con drones

Biztoc.com

Alphabet stock adds $136 billion in market value after it unveils quantum computing breakthrough

Zdnet.co.kr

애플, 사상 최고가...시총 3조7000억 달러 돌파

CNA

China sends largest naval fleet in decades to region, threat level severe, Taiwan says

Globo

PIB da China: valor, composição e série histórica

Biztoc.com

US Strategic Bitcoin Reserve Would Cause Tectonic Shifts In Personal Finance, Researcher Predicts

$Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma$

GlobeNewswire

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma